The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi on delaying cognitive decline does […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!